Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a Healthcare company (Biotechnology) with a market capitalization of $3.9B. The Maz Rating grades it against the other companies in its sector.
Tarsus Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $78.68, Tarsus Pharmaceuticals, Inc. trades at 5.7x sales and 35.1x book value. Over the last twelve months it generated about $682M of revenue and a net loss of $749M. It runs a gross margin of 93.2%, an operating margin of -102.0% and a net margin of -102.9%. It shows return on equity of -245.7%, return on invested capital of -250.0% and a free cash flow yield of 1.0%. On the balance sheet: a debt-to-equity ratio of 0.85 and a current ratio of 1.96. Over the past 52 weeks the share price ranged from $53.89 to $91.53, with a beta of 0.54.
Tarsus Pharmaceuticals, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 1 Strong Buy, 8 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.